Endocrine Fluidity

Main Article Content

Sanjay Kalra
Nitin Kapoor
Atul Dhingra


Type 2 diabetes mellitus (T2DM) is a multifactorial disease. Newer facets of its causation, clinical course, complications and therapy are being unraveled regularly. This editorial describes imeglimin, a first-of-class oxidative phosphorylation inhibitor, that has been approved for T2DM in Japan and India.

Article Details

How to Cite
Sanjay Kalra, Nitin Kapoor, & Atul Dhingra. (2022). Endocrine Fluidity. Indian Journal Of Clinical Practice, 33(7), 8–9. Retrieved from https://ojs.ijcp.in/IJCP/article/view/208
Guest Editorial

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 > >>